版權(quán)說明：本文檔由用戶提供并上傳，收益歸屬內(nèi)容提供方，若內(nèi)容存在侵權(quán)，請進(jìn)行舉報或認(rèn)領(lǐng)
文檔簡介
InvestorUpdate
InvestorRelations
Tel.+416168-88880
Fax+416169-10014
4070BaselSwitzerland
F.Hoffmann-LaRocheLtd
email:
investor.relations@
1/10
AdhocannouncementpursuanttoArt.53LR
Basel,26April2023
Rochereportsstrongsalesgrowthinbasebusinessofbothdivisionsinthefirstquarter;GroupsalesdeclineduetoexpecteddropindemandforCOVID-19tests
●Asexpected,significantlylowerdemandforCOVID-19testsleadstoadecreaseinGroupsales(-3%1atconstantexchangerates[CER]and-7%inSwissfrancs);excludingthiseffect,Groupsalesgrow8%
●PharmaceuticalsDivisionsalesup9%;strongdemandfornewermedicines;Vabysmoforsevereeyediseasesisalreadythestrongestgrowthdriver
●DiagnosticsDivisionbasebusinessgrows4%,whiledivisionalsalesare28%lowerduetoexceptionallyhighdemandforCOVID-19testsinthefirstquarterof2022
●Highlightsinthefirstquarter:
○USapprovalofPolivy(first-linetreatmentforanaggressiveformofbloodcancer)
○EUapprovalofHemlibra(moderatehaemophiliaA)
○PositivephaseIIIdataforVabysmo(retinalveinocclusion,aseriouseyedisease),TecentriqplusAvastin(adjuvanttherapyforcertainformsoflivercancer)andcrovalimab(paroxysmalnocturnalhaemoglobinuria,arareblooddisease)
○Positivefour-yearefficacyandsafetydataforEvrysdi(spinalmuscularatrophy)
○Launchofnewassaystoidentifyclinicallyrelevantmutationsinbraincancers
●Outlookfor2023confirmed
RocheCEOThomasSchinecker:“Wesawstronggrowthinthefirstquarterinbothdivisions’basebusiness,whichlargelycompensatedfortheexpecteddropinsalesofCOVID-19tests.Wemadeprogressinourpipelineinthefirstquarter,especiallyinbloodcancer.Besidesourrecentapprovalsforourbispecificantibodymedicines,LunsumioandColumvi,wehavealsojustreceivedUSapprovalofPolivyasfirst-linetreatmentforanaggressiveformofbloodcancer.Inophthalmology,Vabysmo,amedicineforsevereeyediseases,hasshownpositivephaseIIIdatainretinalveinocclusion.Ifapproved,thiswouldbethethirdindicationforVabysmowhichhasalreadybecomeourstrongestgrowthdriverjustayearafteritslaunch.Weconfirmouroutlookfor2023.”
2/10
Sales
CHFmillions
As%ofsales
%change
January?March2023
2023
2022
2023
2022
AtCER
InCHF
Group
PharmaceuticalsDivision
UnitedStates
Europe
Japan
International*
DiagnosticsDivision
15,322
11,699
5,853
2,071
1,390
2,385
3,623
16,445
11,159
5,489
2,072
1,337
2,261
5,286
100.0
76.438.213.5 9.115.6
23.6
100.0
67.933.412.6 8.113.8
32.1
-3
9
6
5
18
13
-28
-7
5
7
0
4
5
-31
*Asia-Pacific,CEETRIS(CentralEasternEurope,Türkiye,RussiaandIndiansubcontinent),LatinAmerica,MiddleEast,Africa,Canada,others
Outlookfor2023confirmed
DuetothesharpdeclineinsalesofCOVID-19productsofroughlyCHF5billion,RocheexpectsadecreaseinGroupsalesinthelowsingledigitrange(atconstantexchangerates).ExcludingthisCOVID-19salesdecline,Rocheanticipatessolidsalesgrowthinbothdivisions’basebusiness.Coreearningspersharearetargetedtodevelopbroadlyinlinewiththesalesdecline(atconstantexchangerates).RocheexpectstofurtherincreaseitsdividendinSwissfrancs.
Groupresults
Inthefirstthreemonthsoftheyear,Groupsalesdeclinedby3%(-7%inCHF)to
CHF15.3billion.TheappreciationoftheSwissfrancagainstmostcurrencieshadanegativeimpactontheresultsreportedinSwissfrancscomparedtoconstantexchangerates.
Asexpected,thefirstquarter2023resultsreflectedtheexceptionallyhighdemandforCOVID-19testsinthesamequarterof2022,whentheOmicronwavewasatitspeak.
PharmaceuticalsDivisionsalesincreasedmarkedlyby9%toCHF11.7billion,drivenbystrongglobaldemandfornewermedicinestotreatseverediseases.
TheeyemedicineVabysmo,whichwasonlylaunchedinearly2022,becamethedivision’sbiggestgrowthdriver.Thetopfivecontributorstogrowth–Vabysmo,Ocrevus(multiplesclerosis),Hemlibra(haemophilia),Evrysdi(spinalmuscularatrophy)andTecentriq(cancerimmunotherapy)–generatedadditionalsalesofCHF1.1billion.
TheimpactofthecompetitionfrombiosimilarsfortheestablishedcancermedicinesAvastin,HerceptinandMabThera/Rituxansloweddownfurther(combinedapprox.CHF330millionofsalesreduction).
3/10
IntheUnitedStates,salesincreasedby6%.Newermedicines,suchasVabysmo,Ocrevus,HemlibraandthecancermedicinesTecentriqandPhesgo,werethemaincontributors.ThiscontrastedwithdecliningsalesofActemra/RoActemra(COVID-19)andofmedicinesforwhichpatentprotectionhasexpired.
InEurope,saleswereupby5%.GrowthofEvrysdi,Vabysmo,Hemlibra,Phesgo,OcrevusandotherinnovativemedicineswaspartiallyoffsetbylowerRonapreve(COVID-19)salesandthebiosimilarsimpact.
SalesinJapanincreased(+18%),mainlyduetohighersupplyofRonaprevetothegovernmentthaninthepreviousyear,followedbysalesgrowthofPolivy,Tamiflu(influenza),VabysmoandHemlibra.
SalesintheInternationalregionincreasedby13%.ThekeyfactorsweresalesgrowthofPerjeta,Evrysdi,Tamiflu,KadcylaandOcrevus.InChina,saleswereup4%duetohighdemandforTamiflu,
Actemra/RoActemraandXofluza(influenza),whichmorethanoffsettheimpactofbiosimilars.TheDiagnosticsDivision’sbasebusinessrecordedcontinuedgoodgrowth(+4%).
DivisionalsaleswereCHF3.6billion,downby28%assalesofCOVID-19testsdroppedto
CHF0.3billioninthefirstquarterof2023fromCHF1.9billioninthesameperiodlastyear,whendemandwasexceptionallyhigh.
Immunodiagnosticproducts,particularlycardiactests,werethemaingrowthdrivers(+9%).Additionalgrowthimpulsescamefromthevirologybasebusiness(+12%),bloodscreening(+15%)anddiagnosticssolutionsforthedetectionandmonitoringofcervicalcancer(+22%).
ThedeclineinsalesacrossallregionsisprimarilyduetothelowerdemandforCOVID-19tests.TheEurope,MiddleEastandAfrica(EMEA)andNorthAmericaregionsdecreasedby30%and39%,respectively.Asia-Pacificfellby15%;LatinAmericareportedaminusof8%.
Pharmaceuticals:keydevelopmentmilestonesinthefirstquarterof2023
ThePharmaceuticalsDivisionachievedanumberofimportantproductdevelopmentmilestonesinthefirstthreemonthsoftheyear,includingtheUSapprovalofPolivy(aggressiveformofbloodcancer),theEUapprovalofHemlibra(moderatehaemophiliaA)aswellaspositivestudyresultsonVabysmoforaseriousretinalvascularconditionandoncrovalimabinPNH,arare,life-threateningbloodcondition.
4/10
Compound
Milestone
Regulatory
Hemlibra
HaemophiliaA
EU:labelexpansiontoincludemoderatehaemophiliaA
●Hemlibra,alreadyapprovedforseverehaemophiliaAintheEU,willnowalsoprovideaneffectiveandconvenientprophylactictreatmentoptionforpeoplewithmoderatehaemophiliaA
●ModeratehaemophiliaAcanhaveasignificantimpactonthelivesofpeopleaffected,withonly15%livingableed-freelife
●TheapprovalisbasedontheresultsoftheHAVEN6study,whereHemlibrademonstratedeffectivebleedcontrolandafavourablesafetyprofileinpeoplewithmoderatehaemophiliaAwithoutinhibitors
Columvi
Bloodcancer
Columvi(glofitamab)toreceiveapprovalinCanadaforthetreatmentofadultswithrelapsedorrefractorydiffuselargeB-celllymphoma(DLBCL)
●Columvi(glofitamabforinjection)isthefirstCD20xCD3T-cell-engagingbispecificantibodywithfixedtreatmentdurationapprovedinCanadatotreatDLBCL
●AuthorisationisbasedonresultsfromthephaseI/IINP30179study,whichdemonstratedColumviinduceddurableresponseratesinpeoplewithheavilypre-treatedDLBCL
Polivy
Bloodcancer
FDAapprovesPolivyincombinationwithR-CHPforpeoplewithcertaintypesofpreviouslyuntreateddiffuselargeB-celllymphoma
●PolivycombinationisthefirstFDA-approvedtherapyinnearly20yearsforthefirst-linetreatmentofdiffuselargeB-celllymphoma,anaggressivediseaseandthemostcommonformofnon-HodgkinlymphomaintheUS
●POLARIXtrialshowedthePolivycombinationreducedtheriskofdiseaseprogression,relapseordeathby27%comparedtothestandardofcare,R-CHOP,withacomparablesafetyprofile
●First-linetreatmentwithPolivyplusR-CHPhasthepotentialtoreducetheburdenonpatientsandhealthcaresystems,associatedwithdiseaseprogression
PhaseIII,pivotalandotherkeyreadouts
Crovalimab
Haematology
PositivedatafromglobalphaseIIIprogrammeforcrovalimabinparoxysmalnocturnalhaemoglobinuria(PNH),arare,life-threateningbloodcondition
●TheCOMMODORE2studymetitsco-primaryefficacyendpoints,showingthatcrovalimabachieveddiseasecontrolinpeoplewithPNHwhohadnotbeenpreviouslytreatedwithcomplementinhibitors
●TheresultsofthephaseIIICOMMODORE1studyinpeoplewithPNHswitchingfromcurrentlyapprovedC5inhibitorstocrovalimabsupportedthefavourablebenefit-riskprofileofcrovalimab,asseeninthepivotalCOMMODORE2study
●Resultsfrombothstudieswillbesubmittedtoregulatoryauthoritiesaroundtheworldandpresentedatanupcomingmedicalmeeting
Vabysmo
Severeeye
diseases
NewphaseIIIdatashowVabysmorapidlyimprovedvisionandreducedretinalfluidinpeoplewithretinalveinocclusion(RVO)
●Vabysmometitsprimaryendpointintwoclinicaltrials,BALATONandCOMINO,showingnon-inferiorvisualacuitygainscomparedtoaflibercept
●MoreVabysmopatientsdisplayedanabsenceofbloodvesselleakageintheretinacomparedtoafliberceptpatientsinapre-specifiedexploratoryendpoint
5/10
●Ifapproved,RVOwouldbethethirdindicationforVabysmoinadditiontoneovascularor‘wet’age-relatedmaculardegenerationanddiabeticmacularoedema
Evrysdi
Spinalmuscularatrophy
Newfour-yeardataforEvrysdireinforcelong-termefficacyandsafetyprofileinsomeofthemostseverelyaffectedpeoplewithtypes2and3spinalmuscularatrophy(SMA)
●DatafrompivotalSUNFISHstudyshowedthatincreasesinmotorfunctionobservedduringthefirstyearweremaintainedthroughthefourthyear,whiletheoverallrateofadverseeventscontinuedtodecrease
●Dataconfirmlong-termefficacyandsafetyprofileofEvrysdiinabroadrangeofpeoplewithtype2andnon-ambulanttype3SMA
●Morethan8,500people–fromnewbornstotheover60s–havebeentreatedwithEvrysdi,whichisnowapprovedinmorethan90countriesworldwide
Vabysmo
Severeeye
diseases
RochedatahighlightstrengthofophthalmologyportfolioandcommitmenttoadvancingeyecareatARVO2023
●Vabysmodatasuggestrapidandrobustdryingofretinalfluidinpatientswithneovascularor‘wet’age-relatedmaculardegenerationanddiabeticmacularoedema
●Real-worlddataofVabysmodemonstrateitsabilitytoextendtreatmentintervalsinthefirstfourmonthswhilemaintainingvisualacuity
●Clinicaldataonaninvestigationalanti-interleukin-6treatmentinuveiticmacularoedemawillbepresentedforthefirsttime
Tecentriqplus
Avastin
Livercancer
TecentriqplusAvastinreducetheriskofcancerreturninginpeoplewithcertaintypesoflivercancerinaphaseIIIstudy
●Inthefirst-everpositivephaseIIItrialintheadjuvanthepatocellularcarcinoma(HCC)setting,TecentriqplusAvastinreducedtheriskofdiseaserecurrenceby28%
●Upto80%ofpeoplewiththistypeofHCCexperiencediseaserecurrence,atwhichpointtheyarefacedwithpoorerprognosisandshortersurvival
●ThesedatawillbepresentedattheAmericanAssociationforCancerResearch(AACR)AnnualMeeting2023
6/10
Pharmaceuticalssales
Sales
CHFmillions
As%ofsales
%change
January–March2023
2023
2022
2023
2022
AtCER
InCHF
PharmaceuticalsDivision
UnitedStates
Europe
Japan
International*
11,699
5,853
2,071
1,390
2,385
11,159
5,489
2,072
1,337
2,261
100.050.017.711.9
20.4
100.049.218.712.0
20.1
9
6
5
18
13
5
7
0
4
5
*Asia-Pacific,CEETRIS(CentralEasternEurope,Türkiye,RussiaandIndiansubcontinent),LatinAmerica,MiddleEast,Africa,Canada,others
Selectedtop-selling
andnewmedicines
Total
UnitedStates
Europe
Japan
International
CHFm
%
CHFm
%
CHF
m
%
CHFm
%
CHFm
%
Ocrevus
Multiplesclerosis
Perjeta2
Breastcancer
Hemlibra
HaemophiliaA
Tecentriq
CancerimmunotherapyActemra/RoActemra2RA,COVID-19
Ronapreve
COVID-19
Kadcyla2
Breastcancer
Xolair2
Asthma
Herceptin2
BreastandgastriccancerMabThera/Rituxan2Bloodcancer,RA
Vabysmo
Eyediseases(nAMD,DME)
Avastin2
Variouscancertypes
Alecensa
Lungcancer
Evrysdi
Spinalmuscularatrophy
Phesgo
Breastcancer
1,636
1,049
1,034
920
676
567
509
479
477
459
432
416
372
363
241
14
11
24
15
-12
9
5
5
-17
-17
**
-24
9
62
72
1,188
392
631
507
296
-
198
479
91
274
360
133
106
124
98
13
8
21
14
-22
-
-3
5
-37
-21
**
-25
7
13
62
298
220
206
195
193
-
154
-
97
51
44
30
73
113
114
11
1
27
11
-8
-
-6
-
-17
-
-
-45
3
74
59
-
53
92
105
77
567
26
-
9
6
21
91
50
21
-
-
2
24
12
-
33
-8
-
-30
-13
-
-21
5
47
-
150
384
105
113
110
-
131
-
280
128
7
162
143
105
29
32
22
38
34
10
-
42
-
-7
-12
-
-19
14
189
232
7/10
Gazyva/Gazyvaro2
Bloodcancer
Lucentis2
Variouseyediseases
Polivy
Bloodcancer
Enspryng
NMOSD
Rozlytrek
Lungcancer
Xofluza
Influenza
Lunsumio
Bloodcancer
Susvimo
Eyeimplant
197
167
150
54
19
18
14
1
24
-35
96
42
21
**
-
-33
99
167
46
15
10
1
13
1
32
-35
35
16
0
-10
-
-33
55
-
40
4
4
-
2
-
25
-
93
96
80
-
-
-
8
-
51
33
2
-
-
-
-35
-
169
44
5
-
-
-
35
-
13
2
3
17
-1
-
27
-
340
246
144
**
-
-
**Over500%
DME:diabeticmacularoedema/nAMD:neovascularor‘wet’age-relatedmaculardegeneration/NMOSD:neuromyelitisopticaspectrumdisorders/RA:rheumatoidarthritis
Diagnostics:keymilestonesinthefirstquarterof2023
Inthefirstquarteroftheyear,theDiagnosticsDivisionlaunchedimportantproductsintheareasofoncologyandvirology.
Product
Milestone
Regulatory
IDH1R132H
andATRX
antibodies
Braincancer
Launchoftwonewantibodiestoidentifyclinicallyrelevantmutationsinpatientswithbraincancer
●Recentadvancesincancergenomicshavedeepenedthemedicalcommunity’sunderstandingofthemolecularalterationsinbraintumours,more
preciselysubclassifyingpatientsintospecificdiagnoses
●Understandingapatient’sbraintumourmutationstatusintheIDH1andATRXgenesenablesmoreinformedclinicaldecisionsandmayimprovepatientoutcomes
●TheIDH1R132HandATRXantibodiesarethelatestadditionstoRoche’sneuropathologyportfolio,whichcontains29biomarkers
VirSNiPSARS-CoV-2SpikeF486P
COVID-19
LaunchofCOVID-19PCRtesttodetectthefast-spreadingXBB.1.5Omicronsub-variant
●ThisnewtestforresearchersspecificallytargetstheXBB.1.5Omicronsub-variantandrunsonthereal-timePCRplatformsLightCycler480IIandcobasz480
●Resultsfromthetestwillhelptrackthevirus’lineagecloselyandprovideinsightsintotheepidemiologyandtheimpactithasonpublichealth
●ConcernfromtheWorldHealthOrganizationcentresaroundthehightransmissibilityandgrowthadvantageofXBB.1.5
8/10
Collaborations
ElecsysAmyloidPlasmaPanel
Alzheimer’s
disease
CollaborationwithLillytoenhanceearlydiagnosisofAlzheimer’sdisease
●RocheandLillywillcollaborateonthedevelopmentoftheElecsysAmyloidPlasmaPanel
●Thepanelhasdemonstratedclinicalperformanceandiscurrentlyundergoingadditionalinvestigationtoensureclinicalvalidation
●Onceapproved,thepanelcouldhelphealthcareprofessionalstostreamlinethejourneytodiagnosisformorepatients
Diagnosticssales
Sales
CHFmillions
As%ofsales
%change
January–March2023
2023
2022
2023
2022
AtCER
InCHF
DiagnosticsDivision
CustomerAreas3
CoreLab
MolecularLab
PointofCare
DiabetesCare
PathologyLab
Regions
Europe,MiddleEast,Africa
NorthAmerica
Asia-Pacific
LatinAmerica
3,623
1,928
593
397
376
329
1,253
1,029
1,098
243
5,286
1,896
1,189
1,466
417
318
1,902
1,705
1,395
284
100.0
53.116.411.010.49.1
34.628.430.3
6.7
100.0
35.922.527.7 7.96.0
35.932.226.5
5.4
-28
7
-48
-72
-5
7
-30
-39
-15
-8
-31
2
-50
-73
-10
3
-34
-40
-21
-14
FirstQuarterSales2023Webinar
Therewillbealivewebinarforinvestorsandanalyststoday,Wednesday,26Aprilat2:00pmCEST.Toaccessthewebinar,pleaseclick
here
.
AboutRoche
Foundedin1896inBasel,Switzerland,asoneofthefirstindustrialmanufacturersofbrandedmedicines,Rochehasgrownintotheworld’slargestbiotechnologycompanyandthegloballeaderinin-vitrodiagnostics.Thecompanypursuesscientificexcellencetodiscoveranddevelopmedicinesanddiagnosticsforimprovingandsavingthelivesofpeoplearoundtheworld.Weareapioneerinpersonalisedhealthcareandwanttofurthertransformhowhealthcareisdeliveredtohaveanevengreaterimpact.ToprovidethebestcareforeachpersonwepartnerwithmanystakeholdersandcombineourstrengthsinDiagnosticsandPharmawithdatainsightsfromtheclinicalpractice.
9/10
Inrecognisingourendeavortopursuealong-termperspectiveinallwedo,RochehasbeennamedoneofthemostsustainablecompaniesinthepharmaceuticalsindustrybytheDowJonesSustainabilityIndicesforthethirteenthconsecutiveyear.Thisdistinctionalsoreflectsoureffortstoimproveaccesstohealthcaretogetherwithlocalpartnersineverycountrywework.
Genentech,intheUnitedStates,isawhollyownedmemberoftheRocheGroup.RocheisthemajorityshareholderinChugaiPharmaceutical,Japan.
Formoreinformation,pleasevisit
.
Alltrademarksusedormentionedinthisreleaseareprotectedbylaw.
References
[1]Unlessotherwisestated,allgrowthratesandcomparisonstothepreviousyearinthisdocumentareatconstantexchangerates(CER:averagerates2022)andalltotalfiguresquotedarereportedinCHF.
[2]Productslaunchedbefore2015.
[3]CoreLab:diagnosticssolutionsintheareasofimmunoassays,clinicalchemistryandcustombiotechPointofCare:diagnosticssolutionsinemergencyrooms,medicalpracticesordirectlywithpatients
MolecularLab:diagnosticssolutionsforpathogendetectionandmonitoring,donorscreening,sexualhealthandgenomicsDiabetesCare:integratedpersonaliseddiabetesmanagement
PathologyLab:diagnosticssolutionsfortissuebiopsiesandcompaniondiagnostics
Cautionarystatementregardingforward-lookingstatements
Thisdocumentcontainscertainforward-lookingstatements.Theseforward-lookingstatementsmaybeidentifiedbywordssuchas‘believes’,‘expects’,‘a(chǎn)nticipates’,‘projects’,‘intends’,‘should’,‘seeks’,‘estimates’,‘future’orsimilarexpressionsorbydiscussionof,amongotherthings,strategy,goals,plansorintentions.Variousfactorsmaycauseactualresultstodiffermateriallyinthefuturefromthosereflectedinforward-lookingstatementscontainedinthisdocument,suchas:(1)pricingandproductinitiativesofcompetitors;(2)legislativeandregulatorydevelopmentsandeconomicconditions;(3)delayorinabilityinobtainingregulatoryapprovalsorbringingproductstomarket;(4)fluctuationsincurrencyexchangeratesandgeneralfinancialmarketconditions;(5)uncertaintiesinthediscovery,developmentormarketingofnewproductsornewusesofexistingproducts,includingwithoutlimitationnegativeresultsofclinicaltrialsorresearchprojects,unexpectedsideeffectsofpipelineormarketedproducts;(6)increasedgovernmentpricingpressures;(7)interruptionsinproduction;(8)lossoforinabilitytoobtainadequateprotectionforintellectualpropertyrights;(9)litigation;(10)lossofkeyexecutivesorotheremployees;and(11)adversepublicityandnewscoverage.ThestatementregardingearningspersharegrowthisnotaprofitforecastandshouldnotbeinterpretedtomeanthatRoche’searningsorearningspershareforthisoranysubsequentperiodwillnecessarilymatchorexceedthehistoricalpublishedearningsorearningspershareofRoche.
RocheInvestorRelations
Dr.BrunoEschli
Phone:+416168-75284
e-mail:
bruno.eschli@
Dr.SabineBorngr?ber
Phone:+416168-88027
e-mail:
sabine.borngraeber@
10/10
Dr.BirgitMasjost
Phone:+416168-84814
e-mail:
birgit.masjost@
InvestorRelationsNorthAmerica
LorenKalm
Phone:+16502253217
e-mail:
kalm.loren@
Dr.GerardTobin
Phone:+416168-72942
e-mail:
gerard.tobin@
Appendix:Tables
1.SalesJanuarytoMarch2023and2022 2
2.QuarterlysalesandconstantexchangeratesalesgrowthbyDivisionin2023and2022 3
3.ProductsalesPharmaceuticalsDivisionandconstantexchangerategrowthYTDMarch2023vs.YTDMarch2022 4
4.Top20PharmaceuticalsDivisionquarterlyproductsalesandquarterlyconstantexchangeratesalesgrowth 6
5.Top20PharmaceuticalsDivisionquarterlyproductsalesandquarterlyconstantexchangeratesalesgrowthUnitedStates 7
6.Top20PharmaceuticalsDivisionquarterlyproductsalesandquarterlyconstantexchangeratesalesgrowthEurope 8
7.Top20PharmaceuticalsDivisionquarterlyproductsalesandquarterlyconstantexchangeratesalesgrowthJapan 9
8.Top20PharmaceuticalsDivisionquarterlyproductsalesandquarterlyconstantexchangeratesalesgrowthInternational 10
1.SalesJanuarytoMarch2023and2022
Threemonthsended
%change
CHFmillions
31March
2023
2022
AtCER
InCHF
PharmaceuticalsDivision
11,699
11,159
9
5
UnitedStates
5,853
5,489
6
7
Europe
2,071
2,072
5
0
Japan
1,390
1,337
18
4
International*
2,385
2,261
13
5
DiagnosticsDivision
3,623
5,286
-28
-31
RocheGroup
15,322
16,445
-3
-7
*Asia–Pacific,CEETRIS(CentralEasternEurope,Türkiye,RussiaandIndianSub-Continent),LatinAmerica,
MiddleEast,Africa,Canada,others
2.QuarterlysalesandconstantexchangeratesalesgrowthbyDivisionin2023and2022
CHFmillions
%change
%change
%change
%change
%change
Q12022
vs.
Q22022
vs.
Q32022
vs.
Q42022
vs.
Q12023
vs.
Q12021
Q22021
Q32021
Q42021
Q12022
PharmaceuticalsDiv.
11,159
6
11,188
0
10,842
-6
12,362
9
11,699
9
UnitedStates
5,489
2
5,874
1
5,836
-6
6,123
1
5,853
6
Europe
2,072
-1
2,032
-6
1,996
4
2,043
-3
2,071
5
Japan
1,337
69
865
3
827
-27
1,920
69
1,390
18
International*
2,261
0
2,417
4
2,183
-3
2,276
4
2,385
13
DiagnosticsDivision
5,286
24
4,662
0
3,900
-4
3,882
-9
3,623
-28
RocheGroup
16,445
11
15,850
0
14,742
-6
16,244
4
15,322
-3
*Asia–Pacific,CEETRIS(CentralEasternEurope,Türkiye,RussiaandIndianSub-Continent),LatinAmerica,MiddleEast,Africa,Canada,others
3.ProductsalesPharmaceuticalsDivisionandconstantexchangerategrowthYTDMarch2023vs.YTDMarch2022
Total
UnitedStates
Europe
Japan
International*
CHFmillions
CHFm
%
CHFm
%
CHFm
%
CHFm
%
CHFm
%
Ocrevus
1,636
14
1,188
13
298
11
-
-
150
32
Perjeta
1,049
11
392
8
220
1
53
2
384
22
Hemlibra
1,034
24
631
21
206
27
92
24
105
38
Tecentriq
920
15
507
14
195
11
105
12
113
34
Actemra/RoActemra
676
-12
296
-22
193
-8
77
-
110
10
Ronapreve
567
9
-
-
-
-
567
33
-
-
Kadcyla
509
5
198
-3
154
-6
26
-8
131
42
Xolair
479
5
479
5
-
-
-
-
-
-
Herceptin
477
-17
91
-37
97
-17
9
-30
280
-7
MabThera/Rituxan
459
-17
274
-21
51
-
6
-13
128
-12
Vabysmo
432
**
360
**
44
-
21
-
7
-
Avastin
416
-24
133
-25
30
-45
91
-21
162
-19
Alecensa
372
9
106
7
73
3
50
5
143
14
Evrysdi
363
62
124
13
113
74
21
47
105
189
Activase/TNKase
302
23
288
23
-
-
-
-
14
17
Phesgo
241
72
98
62
114
59
-
-
29
232
Gazyva
197
24
99
32
55
25
8
-35
35
27
Lucentis
167
-35
167
-35
-
-
-
-
-
-
Polivy
150
96
46
35
40
93
51
169
13
340
Pulmozyme
127
-5
83
-5
20
-16
-
-
24
10
Enspryng
54
42
15
16
4
96
33
44
2
246
Rozlytrek
19
21
10
0
4
80
2
5
3
144
Xofluza
18
**
1
-10
-
-
-
-
17
**
Lunsumio
14
-
12
-
2
-
-
-
-
-
Cotellic
12
-2
5
21
3
-17
-
-
4
-9
Gavreto
10
95
6
48
2
83
-
-
2
**
Luxturna
4
-23
4
-23
-
-
-
-
-
-
Susvimo
1
-33
1
-33
-
-
-
-
-
-
Pharmaother
994
-15
239
-38
153
-20
178
4
424
2
Pharmatotalsales
11,699
9
5,853
6
2,071
5
1,390
18
2,385
13
*Asia–Pacific,CEETRIS(CentralEasternEurope,Türkiye,RussiaandIndianSub-Continent),LatinAmerica,MiddleEast,Africa,Canada,others**Over500%
4.Top20PharmaceuticalsDivisionquarterlyproductsalesandquarterlyconstantexchangeratesalesgrowth
CHFmillions
Q12022
%change
vs.
Q12021
Q22022
%change
vs.
Q22021
Q32022
%change
vs.
Q32021
Q42022
%change
vs.
Q42021
Q12023
%change
vs.
Q12022
Ocrevus
1,449
18
1,461
17
1,517
16
1,609
18
1,636
14
Perjeta
993
1
1,068
9
1,029
5
997
4
1,049
11
Hemlibra
853
30
973
31
952
23
1,045
24
1,034
24
Tecentriq
825
8
933
13
934
9
1,025
24
920
15
Actemra/RoActemra
792
3
663
-23
584
-42
662
-22
676
-12
Ronapreve
587
272
22
-91
22
-92
1,048
118
567
9
Kadcyla
511
9
563
18
516
6
490
-3
509
5
Xolair
456
9
569
13
600
8
583
6
479
5
Herceptin
607
-19
572
-11
493
-23
470
-22
477
-17
MabThera/Rituxan
564
-21
553
-20
479
-19
479
-20
459
-17
Vabysmo
21
-
88
-
173
-
309
-
432
*
Avastin
581
-32
561
-27
510
-28
470
-25
416
-24
Alecensa
361
23
384
16
382
11
386
10
372
9
Evrysdi
226
189
274
65
293
93
326
59
363
62
Activase/TNKase
247
-20
312
1
322
-5
296
-27
302
23
Phesgo
146
410
179
168
201
76
214
73
241
72
Gazyva
165
7
184
9
190
9
191
9
197
24
Lucentis
256
-26
316
-9
228
-39
212
-40
167
-35
Polivy
81
89
96
93
113
63
147
97
150
96
Pulmozyme
136
-3
143
2
135
-3
129
-15
127
-5
*Over500%
5.Top20PharmaceuticalsDivisionquarterlyproductsalesandquarterlyconstantexchangeratesalesgrowthUnitedStates
CHFmillions
%change
%change
%change
%change
%change
Q12022
vs.
Q22022
vs.
Q32022
vs.
溫馨提示
- 1. 本站所有資源如無特殊說明，都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等，如果需要附件，請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙，網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽，若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間，僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理，對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯，并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容，請與我們聯(lián)系，我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 2025年幼兒園教師學(xué)生健康監(jiān)測與疾病預(yù)防合同
- 迪慶云南迪慶香格里拉市招聘治安聯(lián)防人員80人筆試歷年參考題庫附帶答案詳解
- 蘇州江蘇蘇州大學(xué)納米科學(xué)技術(shù)學(xué)院課程助教招聘11人（202420252學(xué)期）筆試歷年參考題庫附帶答案詳解
- 舟山浙江舟山市普陀區(qū)機(jī)關(guān)事務(wù)管理中心編外人員招聘筆試歷年參考題庫附帶答案詳解
- 紅河2025年云南紅河金平縣人民法院招聘聘用制書記員司法警務(wù)輔助人員筆試歷年參考題庫附帶答案詳解
- 福建2025年福建水利電力職業(yè)技術(shù)學(xué)院招聘35人筆試歷年參考題庫附帶答案詳解
- 湖北2025年湖北民族大學(xué)人才引進(jìn)163人筆試歷年參考題庫附帶答案詳解
- 浙江2025年春季浙江省新時代自貿(mào)港研究院招聘筆試歷年參考題庫附帶答案詳解
- 河南2024年河南體育學(xué)院冬季運(yùn)動管理中心人事代理招聘11人筆試歷年參考題庫附帶答案詳解
- 桂林2025年廣西桂林市事業(yè)單位招聘1462人筆試歷年參考題庫附帶答案詳解
- 基礎(chǔ)護(hù)理：皮下注射法
- 2022年甘肅省蘭州市診斷考試（一診）數(shù)學(xué)試題（含答案解析）
- 工業(yè)企業(yè)職工聽力保護(hù)規(guī)范
- 裝載機(jī)裝車施工方案
- 《工程估價》課程設(shè)計(jì)
- 語文新課標(biāo)背景下：六上《每日閱讀打卡表》（模板）
- 二年級綜合實(shí)踐活動課件-我與蔬菜交朋友-全國通(41張)
- 血型與輸血檢驗(yàn)-臨床輸血（臨床檢驗(yàn)課件）
- 良性前列腺增生癥住院醫(yī)師規(guī)范化培訓(xùn)教學(xué)查房
- 高中數(shù)學(xué)知識點(diǎn)大全
- 人機(jī)料法環(huán)測5M1E分析法
評論
0/150
提交評論